What can we learn from phase II adjuvant trials in melanoma?
(2000) The British journal of cancer — Vol. 83, n° 1, p. 6-7 (2000)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- In this issue of the Journal, McClay and colleagues report on a clinical trial of adjuvant treatment with cisplatin and tamoxifen in 153 melanoma patients stages II to IV (McClay et al, 2000). This study has several important limitations, since it is not randomized and has no control arm. The authors nevertheless suggest a beneficial;il effect of treatment on disease-free and overall survival. The design of this trial deserves consideration acknowledging the information available on adjuvant treatment of melanoma at the time the study was initiated, and the report needs to be examined from the perspective of today, the time the study is reported.
- Affiliations
Citations
Keilholz, U., Suciu, S., & Eggermont, A. (2000). What can we learn from phase II adjuvant trials in melanoma? The British journal of cancer, 83(1), 6-7. https://doi.org/10.1054/bjoc.2000.1277 (Original work published 2000)